Neoprobe (NYSE Amex: NEOP) remains on track to file a New Drug Application for its drug used for cancer detection, Lymphoseek, sometime in the third quarter. Factoring in the customary 10-month review ...

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on September 15, Neoprobe Corp.'s Director, Peter F Drake, ...

Cancer diagnostics company Neoprobe (NYSE Amex:NEOP) reported a $2.2 million loss in the second quarter, but with this company the financials rarely tell much of the story. The company’s primary focus ...

DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today released the text of its ...

DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that its common stock has been ...

The company submitted its marketing application on Aug 10, so it should hear back from the FDA in the beginning of October about whether the application was accepted. Assuming a standard 10-month ...

DUBLIN, Ohio--(BUSINESS WIRE)-- Neoprobe Corporation (NYSE: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that a multi-center Phase 3 study of ...

After five straight years of multimillion-dollar losses, executives at a tiny Dublin biotech outfit sound upbeat. "It's just a great product and a great little company," said Carl Aschinger Jr., ...

Neoprobe Corp. said Monday it has approval to resume production of its long-stalled cancer-detecting drug Rigscan, with an eye toward human trials next year. Neoprobe Corp. said Monday it has approval ...

Earlier this month, Neoprobe (ASE: NEOP) completed the sale of its handheld gamma radiation detector business to Devicor Medical Products. The company pocketed $30 million up-front with the potential ...

Add Yahoo as a preferred source to see more of our stories on Google. The sale transforms Neoprobe into a pure-play drug developer, although it's sticking with its radiation roots. Neoprobe's lead ...